A leading expert on head and neck oncology provides her initial impressions on the case of a 64-year-old woman with differentiated thyroid cancer.
Case: A 64-Year-Old Woman with DTC
Initial presentation
Clinical workup and initial treatment
Subsequent treatment and follow-up
This is a video synopsis/summary of a Case-Based Peer Perspective featuring Lori Wirth, MD.
Wirth presents a case of a 64-year-old woman with a past medical history of hyperlipidemia and chronic obstructive pulmonary disease. The patient presented with a painless lump and occasional swelling in her neck, which was discovered to be a 3.3-cm suspicious right thyroid mass and 2 suspicious supraclavicular lymph nodes. Fine needle aspiration revealed papillary thyroid carcinoma (PTC). The patient underwent a total thyroidectomy with node dissection, and pathology showed a 3-cm columnar cell variant PTC with positive lymph nodes, staged as T2N1BM0. Despite treatment with 150 mCi of radioactive iodine (RAI), the patient had an elevated thyroglobulin level and small bilateral lung nodules on chest CT, indicating RAI-refractory thyroid cancer. Next-generation sequencing did not reveal actionable mutations or gene rearrangements. Due to increasing thyroglobulin levels and growing lung nodules, the patient was started on lenvatinib at 24 mg per day.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Wirth Explores Challenges of Therapy Selection for RAI-Refractory Differentiated Thyroid Cancer
June 28th 2024During a Case-Based Roundtable® event, Lori J. Wirth, MD, discussed with participants how they approach use of lenvatinib and other therapy for patients with radioactive iodine–refractory differentiated thyroid cancer.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More